GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Book Value per Share

Macrogenics (Macrogenics) Book Value per Share : $2.46 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Book Value per Share?

Macrogenics's book value per share for the quarter that ended in Dec. 2023 was $2.46.

During the past 12 months, Macrogenics's average Book Value Per Share Growth Rate was 6.80% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -22.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -17.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Macrogenics was 35.00% per year. The lowest was -22.40% per year. And the median was -13.90% per year.

Macrogenics's current price is $14.37. Its book value per share for the quarter that ended in Dec. 2023 was $2.46. Hence, today's PB Ratio of Macrogenics is 5.84.

During the past 13 years, the highest P/B Ratio of Macrogenics was 12.83. The lowest was 0.79. And the median was 3.16.


Macrogenics Book Value per Share Historical Data

The historical data trend for Macrogenics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Book Value per Share Chart

Macrogenics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 5.26 3.91 2.30 2.46

Macrogenics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.30 1.77 2.77 3.13 2.46

Competitive Comparison of Macrogenics's Book Value per Share

For the Biotechnology subindustry, Macrogenics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Macrogenics's PB Ratio falls into.



Macrogenics Book Value per Share Calculation

Macrogenics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(152.61-0.00)/62.07
=2.46

Macrogenics's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(152.61-0.00)/62.07
=2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Macrogenics  (NAS:MGNX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Macrogenics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Macrogenics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Macrogenics (Macrogenics) Business Description

Traded in Other Exchanges
Address
9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.
Executives
Ezio Bonvini officer: Sr VP, Research & CSO 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz director
Jeffrey Stuart Peters officer: Acting General Counsel 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu director C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels officer: SVP, CFO and Secretary 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel officer: Sr VP, BPD & Manufacturing 9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb 10 percent owner SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser officer: Sr VP & Chief Business Officer 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith director OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck officer: Chief Medical Officer 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949